Drug Interaction Report

GENERALLY AVOID: The use of systemic corticosteroids may reduce the efficacy of afamitresgene autoleucel, an autologous T-cell immunotherapy agent. The exact mechanism by which corticosteroids exert this effect is not clearly described; however, it may involve corticosteroid-induced T lymphocyte apoptosis. The clinical trial that evaluated the efficacy of afamitresgene autoleucel excluded patients who were on systemic corticosteroids for at least 14 days prior to leukapheresis and lymphodepletion. Therefore, clinical data examining the use of systemic corticosteroids prior to or during an infusion of afamitresgene autoleucel are not available.

MANAGEMENT: The manufacturer of afamitresgene autoleucel recommends avoiding the prophylactic use of systemic corticosteroids. Consultation with institutional protocols, national guidelines, and package labeling may be helpful.